European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

[1]  A. Horwich,et al.  Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  C. Bokemeyer,et al.  Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Warde,et al.  Evidence‐based guidelines for following stage 1 seminoma , 2007, Cancer.

[4]  S. Culine,et al.  Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. Huddart,et al.  Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Hall,et al.  Noncancer causes of death in survivors of testicular cancer. , 2007, Journal of the National Cancer Institute.

[7]  S. Culine,et al.  Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. , 2007, European urology.

[8]  L. Einhorn,et al.  Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Motzer,et al.  Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Fosså,et al.  Late relapses of germ cell malignancies: incidence, management, and prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Giwercman,et al.  Sperm DNA integrity in testicular cancer patients. , 2006, Human reproduction.

[12]  E. Rutherford,et al.  Late relapse of metastatic non-seminomatous testicular germ cell tumours. , 2006, Clinical radiology.

[13]  S. Fosså,et al.  Components of the metabolic syndrome in long-term survivors of testicular cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  G. Bartsch,et al.  Two cycles of cisplatin‐based chemotherapy for low‐volume retroperitoneal stage II nonseminomatous germ cell tumours , 2006, BJU international.

[15]  W. Oyen,et al.  Commonly used imaging techniques for diagnosis and staging. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Fimmers,et al.  One course of adjuvant PEB chemotherapy versus retroperitoneal lymph node dissection in patients with stage I non-seminomatous germ-cell tumors (NSGCT): Results of the German Prospective Multicenter Trial (Association of Urological Oncology [AUO]/German Testicular Cancer Study Group [GTCSG] Trial 01 , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Huddart,et al.  A prospective study of 18FDG PET in the prediction of relapse in patients with high risk clinical stage I (CS1) non-seminomatous germ cell cancer (NSGCT): MRC study TE22. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M Mazumdar,et al.  Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Fosså,et al.  Late recurrences of germ cell malignancies: a population-based experience over three decades , 2006, British Journal of Cancer.

[20]  P. Albers,et al.  Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  F. V. van Leeuwen,et al.  Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Smit,et al.  Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  L. Paz-Ares,et al.  Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  J. Carles,et al.  Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Fosså,et al.  Paternity following treatment for testicular cancer. , 2005, Journal of the National Cancer Institute.

[26]  M. Goldstein,et al.  Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. , 2005, The Journal of urology.

[27]  J. Bacik,et al.  Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  John D Boice,et al.  Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. , 2005, Journal of the National Cancer Institute.

[29]  J. Bacik,et al.  Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Huddart,et al.  Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. , 2005, The New England journal of medicine.

[31]  D. Krewski,et al.  Epidemiology of testicular cancer: An overview , 2005, International journal of cancer.

[32]  T. Wilsgaard,et al.  Blood pressure and body mass index in long-term survivors of testicular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  N. Weiss,et al.  Subfertility and the risk of testicular germ cell tumors (United States) , 2005, Cancer Causes & Control.

[34]  G. Rustin,et al.  Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial , 2005, The Lancet.

[35]  Jinbo Chen,et al.  Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. , 2005, Journal of the National Cancer Institute.

[36]  D. Dearnaley,et al.  Fertility, gonadal and sexual function in survivors of testicular cancer , 2005, British Journal of Cancer.

[37]  W. Siegert,et al.  A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  W. Brenner,et al.  18F]-FDG-PET in clinical stage I and II non-seminomatous germ cell tumors: First results of the German Multicenter Trial , 2005 .

[39]  N. Skakkebaek,et al.  Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  M. Kattan,et al.  Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J. Crown,et al.  Pelvic recurrence in stage I seminoma: A new phenomenon that questions modern protocols for radiotherapy and follow‐up , 2005, International journal of urology : official journal of the Japanese Urological Association.

[42]  C. Bokemeyer,et al.  Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[43]  P. Albers,et al.  Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. , 2005, The Journal of urology.

[44]  S. Fosså,et al.  Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Smit,et al.  Left ventricular and cardiac autonomic function in survivors of testicular cancer , 2005, European journal of clinical investigation.

[46]  I. Sesterhenn,et al.  World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .

[47]  M. Hentrich,et al.  Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich , 2005, Acta oncologica.

[48]  D. Ornstein.  Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs , 2004 .

[49]  S. Culine,et al.  Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  W. Siegert,et al.  European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  J. Bachaud,et al.  Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. , 2004, European urology.

[52]  G. Mikuz,et al.  Handling and reporting of biopsy and surgical specimens of testicular cancer. , 2004, European urology.

[53]  P. Albers,et al.  Late relapse of testicular cancer , 2004, World Journal of Urology.

[54]  U. Pichlmeier,et al.  Clinical epidemiology of testicular germ cell tumors , 2004, World Journal of Urology.

[55]  K. Hemminki,et al.  Familial risk in testicular cancer as a clue to a heritable and environmental aetiology , 2004, British Journal of Cancer.

[56]  C. Bokemeyer,et al.  2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  M. Williams,et al.  Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. , 2004, Urology.

[58]  G. Bartsch,et al.  Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience. , 2004, Urology.

[59]  V. Nargund,et al.  Re: Leroy X, Rigot J-M, Aubert S, Ballereau C, Gosselin B. Value of frozen section examination for the management of nonpalpable incidental testicular tumors. Eur. Urol. 2003;44:458-60. , 2004, European urology.

[60]  Andrew K. Lee,et al.  Mortality after cure of testicular seminoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  J. Bacik,et al.  Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  L. Einhorn,et al.  Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  S. Aubert,et al.  Value of frozen section examination for the management of nonpalpable incidental testicular tumors. , 2003, European urology.

[64]  R. Motzer,et al.  Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors. , 2003, The Journal of urology.

[65]  A. Mykletun,et al.  Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. , 2003, European urology.

[66]  G. Bartsch,et al.  Frozen section analysis-guided organ-sparing approach in testicular tumors: technique, feasibility, and long-term results. , 2003, Urology.

[67]  S. Fosså,et al.  Testicular carcinoma in situ in patients with extragonadal germ-cell tumours: the clinical role of pretreatment biopsy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  N. Skakkebaek,et al.  Histological evidence of testicular dysgenesis in contralateral biopsies from 218 patients with testicular germ cell cancer , 2003, The Journal of pathology.

[69]  B. Leibovich,et al.  Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? , 2003, The Journal of urology.

[70]  I. Bodrogi,et al.  The incidence, prognosis, clinical and histological characteristics, treatment, and outcome of patients with bilateral germ cell testicular cancer in Hungary , 2003, Journal of Cancer Research and Clinical Oncology.

[71]  P. Albers,et al.  Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. , 2003, The Journal of urology.

[72]  D P Dearnaley,et al.  Cardiovascular disease as a long-term complication of treatment for testicular cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  R. Fimmers,et al.  Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  R. Souchon,et al.  Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group , 2003, British Journal of Cancer.

[75]  J. Habbema,et al.  External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients , 2003, British Journal of Cancer.

[76]  L. Collette,et al.  Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  C. Meisner,et al.  Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  M. Ro̸rth,et al.  Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[79]  M. Bergmann,et al.  Update on the diagnostic safety for detection of testicular intraepithelial neoplasia (TIN) , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[80]  J. Sheinfeld.  The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. , 2002, Seminars in urologic oncology.

[81]  C. Meyer,et al.  Imaging of intrathoracic metastases of nonseminomatous germ cell tumors. , 2002, Chest surgery clinics of North America.

[82]  S. Fosså,et al.  Gonadal function and fertility in patients with bilateral testicular germ cell malignancy. , 2002, European urology.

[83]  D. Dearnaley,et al.  Late recurrence in 1263 men with testicular germ cell tumors , 2002, Cancer.

[84]  S. Fosså,et al.  Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[85]  P. Oakeshott,et al.  Pilot study of testicular cancer awareness and testicular self-examination in men attending two South London general practices. , 2002, Family practice.

[86]  H. G. van der Poel,et al.  Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors. , 2002, Urology.

[87]  W. Burchert,et al.  Diagnostic Value of 18F-FDG Positron Emission Tomography for Detection and Treatment Control of Malignant Germ Cell Tumors , 2002, Urologia Internationalis.

[88]  W. Siegert,et al.  High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[89]  M. Ro̸rth,et al.  Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  D. Dearnaley,et al.  Metastatic nonseminomatous germ cell tumors of the testis , 2002, Cancer.

[91]  P. Olbert,et al.  Accuracy of frozen section examination of testicular tumors of uncertain origin. , 2002, European urology.

[92]  S. Fosså,et al.  Long-term renal function after treatment for malignant germ-cell tumours. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[93]  D. Strumberg,et al.  Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[94]  C. Logothetis,et al.  Germ-cell tumor survivors: the price for cure. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[95]  U. Studer,et al.  Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[96]  P. Albers,et al.  Organ sparing surgery for malignant germ cell tumor of the testis. , 2001, The Journal of urology.

[97]  S. Fosså,et al.  Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. , 2001, Journal of the National Cancer Institute.

[98]  A. Pollack,et al.  Radiotherapy for stage II testicular seminoma. , 2001, International journal of radiation oncology, biology, physics.

[99]  C. Bokemeyer,et al.  Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  S. Culine,et al.  Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  R. Motzer,et al.  Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  A. Hobisch,et al.  Laparoscopic retroperitoneal lymph node dissection. , 2001, Journal of endourology.

[103]  H S Koops,et al.  Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era , 2001, Cancer.

[104]  J. Carles,et al.  E400P in advanced seminoma of good prognosis according to the international germ cell cancer collaborative group (IGCCCG) classification: the Spanish Germ Cell Cancer Group experience. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[105]  A. Horwich,et al.  Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[106]  H. Maase.  Do we have a new standard of treatment for patients with seminoma stage IIA and stage IIB , 2001 .

[107]  S. Culine,et al.  Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse. , 2001, European journal of cancer.

[108]  J. Logue,et al.  The effect of radiotherapy treatment changes on sites of relapse in stage I testicular seminoma. , 2001, Clinical radiology.

[109]  F. Burkhard,et al.  Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. , 2001, The Journal of urology.

[110]  J. Olsen,et al.  Risk of testicular cancer in men with abnormal semen characteristics: cohort study , 2000, BMJ : British Medical Journal.

[111]  P. Albers,et al.  Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. , 2000, The Journal of urology.

[112]  S. Culine,et al.  The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. , 2000, European journal of cancer.

[113]  M. Bains,et al.  Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  C. Bokemeyer,et al.  First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[115]  L. Weissbach,et al.  RPLND or Primary Chemotherapy in Clinical Stage IIA/B Nonseminomatous Germ Cell Tumors? , 2000, European Urology.

[116]  D J van Veldhuisen,et al.  Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  M. Bains,et al.  Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  P. Alken,et al.  Long–Term Experience with Laparoscopic Retroperitoneal Lymph Node Dissection in the Management of Low–Stage Testis Cancer , 2000, European Urology.

[119]  S. Rodenhuis,et al.  Management of intermediate‐prognosis germ‐cell cancer: Results of a phase I/II study of Taxol‐BEP , 1999, International journal of cancer.

[120]  J. Pont,et al.  Impact of cytotoxic treatment on long‐term fertility in patients with germ‐cell cancer , 1999, International journal of cancer.

[121]  J. Habbema,et al.  Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer , 1999, International journal of cancer.

[122]  C. Meisner,et al.  Radiotherapy for stages I and IIA/B testicular seminoma , 1999, International journal of cancer.

[123]  C. Stief,et al.  Management of the post‐chemotherapy residual mass in patients with advanced stage non‐seminomatous germ cell tumors (nsgct) , 1999, International journal of cancer.

[124]  L. Weissbach,et al.  Prognostic Factors in Seminomas with Special Respect to HCG: Results of a Prospective Multicenter Study , 1999, European Urology.

[125]  R. Günther,et al.  Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients. , 1999, Urology.

[126]  C. Meisner,et al.  First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  P. Bossuyt,et al.  Empirical evidence of design-related bias in studies of diagnostic tests. , 1999, JAMA.

[128]  S. Fosså,et al.  Health-related quality of life in patients treated for testicular cancer. , 1999, Current opinion in urology.

[129]  Norbert Avril,et al.  Relevance of Positron Emission Tomography (PET) in Oncology , 1999, Strahlentherapie und Onkologie.

[130]  Wan Ariffin Bin Abdullah,et al.  Med Pediatr Oncol , 1999 .

[131]  M. Dietlein,et al.  [The lymph node staging of malignant testicular germ-cell tumors]. , 1999, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[132]  M. Williams,et al.  Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours , 1999, British Journal of Cancer.

[133]  L. Collette,et al.  Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. , 1999, Journal of the National Cancer Institute.

[134]  C. Bokemeyer,et al.  Long-term effects on sexual function and fertility after treatment of testicular cancer , 1999, British Journal of Cancer.

[135]  A. Horwich,et al.  Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  S. Fosså,et al.  Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  D. Böhlen,et al.  Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. , 1999, The Journal of urology.

[138]  G. Howard,et al.  Imaging of the thorax in the management of germ cell testicular tumours. , 1999, Clinical radiology.

[139]  P. Albers,et al.  Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. , 1999, Urology.

[140]  S. Fosså,et al.  Treatment outcome of patients with brain metastases from malignant germ cell tumors , 1999, Cancer.

[141]  L. Collette,et al.  Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. , 1998, British Journal of Cancer.

[142]  S. Fosså,et al.  Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. , 1998, The Journal of urology.

[143]  S. Fosså,et al.  Postchemotherapy residual masses in germ cell tumor patients , 1998, Cancer.

[144]  L. Collette,et al.  Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. , 1998, British Journal of Cancer.

[145]  G. Bauman,et al.  Postoperative radiotherapy for Stage I/II seminoma: results for 212 patients. , 1998, International journal of radiation oncology, biology, physics.

[146]  F. Mostofi,et al.  Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis , 1998, Cancer.

[147]  L. Einhorn,et al.  Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. , 1998, Urology.

[148]  B. Lowe,et al.  A rational approach to managing stage I nonseminomatous germ cell cancer. , 1998, The Urologic clinics of North America.

[149]  J. Donohue,et al.  Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy? , 1998, The Urologic clinics of North America.

[150]  L. Einhorn,et al.  Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[151]  J. Ong,et al.  Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumours. , 1998, British journal of urology.

[152]  D Jacqmin,et al.  Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles--initial clinical experience. , 1998, Radiology.

[153]  H. von der Maase,et al.  Effect of chemotherapy on carcinoma in situ of the testis. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[154]  D. Ondruš,et al.  Prognostic Factors in Clinical Stage I Nonseminomatous GermCell Testicular Tumors: Rationale for Different Risk-Adapted Treatment , 1998, European Urology.

[155]  P. Catalano,et al.  Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  N. Skakkebaek,et al.  Gonadal function in men with testicular cancer. , 1998, Seminars in oncology.

[157]  L. Einhorn,et al.  Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[158]  J. Beyer,et al.  Prognostic factors in metastatic germ cell tumors. , 1998, Seminars in oncology.

[159]  Jewett Ma,et al.  Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. , 1998 .

[160]  H. Thaler,et al.  Clinical stage I testis cancer: long-term outcome of patients on surveillance. , 1998, The Journal of urology.

[161]  R Sylvester,et al.  Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[162]  L. Collette,et al.  Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[163]  A. Belldegrun,et al.  Positron emission tomography in urological oncology. , 1998, The Journal of urology.

[164]  R. Paterson,et al.  Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient? , 1998, British journal of urology.

[165]  K. Dieckmann,et al.  The value of the biopsy of the contralateral testis in patients with testicular germ cell cancer: The recent German experience , 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[166]  L. Hertle,et al.  Semen parameters and testicular pathology in men with testicular cancer and contralateral carcinoma in situ or bilateral testicular malignancies. , 1997, Human reproduction.

[167]  U. Pichlmeier,et al.  The prevalence of familial testicular cancer , 1997, Cancer.

[168]  P. Hall,et al.  Risk of second malignant neoplasms among long-term survivors of testicular cancer. , 1997, Journal of the National Cancer Institute.

[169]  H. Herr,et al.  Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer? , 1997, British journal of urology.

[170]  S. Follin,et al.  Acute Pain Management: Operative or Medical Procedures and Trauma , 1997, The Annals of pharmacotherapy.

[171]  C. Meisner,et al.  Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: A prospective multicenter study , 1997 .

[172]  F. Mostofi,et al.  Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors. , 1997, The Journal of urology.

[173]  J. Pont,et al.  Fertility after chemotherapy for testicular germ cell cancer. , 1997, Fertility and sterility.

[174]  R. Motzer,et al.  Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[175]  O. Dahl,et al.  Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer. , 1997, European journal of cancer.

[176]  C. Bokemeyer,et al.  Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[177]  C. Catton,et al.  Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. , 1997, The Journal of urology.

[178]  L. Collette,et al.  Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[179]  F. Sedlmayer,et al.  Endocrine profiles after radiotherapy in stage I seminoma: impact of two different radiation treatment modalities. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[180]  A. Horwich,et al.  Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. , 1997, European journal of cancer.

[181]  C. Bokemeyer,et al.  Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. , 1997, European journal of cancer.

[182]  R. Fimmers,et al.  MIB‐1 immunohistochemistry in clinical Stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis , 1997 .

[183]  S. Fosså,et al.  Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  R. Sagerman,et al.  Long-term evaluation of postorchiectomy radiotherapy for stage II seminoma. , 1997, American journal of clinical oncology.

[185]  C. Bokemeyer,et al.  Treatment of brain metastases in patients with testicular cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[186]  L. Einhorn,et al.  Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[187]  L. Einhorn,et al.  Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[188]  R. Motzer,et al.  Surgery for a post-chemotherapy residual mass in seminoma. , 1997, The Journal of urology.

[189]  J. Best,et al.  The role of computed tomographic examination of the pelvis in the management of testicular germ cell tumours. , 1997, Clinical radiology.

[190]  Richard Sylvester,et al.  International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers , 1997 .

[191]  K. Dieckmann,et al.  Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[192]  J. Olsen,et al.  Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population‐based study , 1996, International journal of cancer.

[193]  I. Kiricuta,et al.  Omission of the pelvic irradiation in stage I testicular seminoma: a study of postorchiectomy paraaortic radiotherapy. , 1996, International journal of radiation oncology, biology, physics.

[194]  M. Williams,et al.  Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[195]  J. Donohue,et al.  Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors. , 1996, The Journal of urology.

[196]  J. Pont,et al.  Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[197]  P. Albers,et al.  Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumors. , 1996, The Journal of urology.

[198]  M. Mazumdar,et al.  Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[199]  K. Kopecky,et al.  Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. , 1995, The Journal of urology.

[200]  S. Kaye,et al.  Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours? , 1995, British journal of urology.

[201]  J. Donohue,et al.  The clinical implications of procedural deviations during orchiectomy for nonseminomatous testis cancer. , 1995, The Journal of urology.

[202]  P. Goodman,et al.  Stage I testicular seminoma: results of adjuvant irradiation and surveillance. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[203]  N. Nicolai,et al.  A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup. , 1995, The Journal of urology.

[204]  J P Donohue,et al.  Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[205]  M. Horowitz,et al.  The effects of abdominal irradiation for seminoma of the testis on gastrointestinal function , 1995, Journal of gastroenterology and hepatology.

[206]  G. Kerr,et al.  Radiotherapy for stages I and II testicular seminoma: results and morbidity in 238 patients. , 1995, The British journal of radiology.

[207]  G. Robertson.  Radical orchidectomy and benign testicular conditions , 1995, The British journal of surgery.

[208]  Peter Clark,et al.  Original Articles: Testis Cancer: A Review of Scrotal Violation in Testicular Cancer: Is Adjuvant Local Therapy Necessary? , 1995 .

[209]  G. Mead,et al.  Orchiectomy after chemotherapy in patients with metastatic testicular cancer. Is it indicated? , 1995, Cancer.

[210]  P. Albers,et al.  Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors , 1994, Cancer.

[211]  D. Bajorin,et al.  Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors , 1994, Cancer.

[212]  J. Donohue,et al.  Complications of primary retroperitoneal lymph node dissection. , 1994, The Journal of urology.

[213]  R. Motzer,et al.  Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy , 1994, Cancer.

[214]  B. Kennedy,et al.  Adjuvant chemotherapy for stage II nonseminomatous germ cell cancer of the testis , 1994, Cancer.

[215]  J. Moul,et al.  Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. , 1994, Cancer research.

[216]  C. Perez,et al.  Radiation therapy for stage I and IIA testicular seminoma. , 1994, International journal of radiation oncology, biology, physics.

[217]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[218]  H. Schraffordt koops,et al.  Magnetic resonance imaging of retroperitoneal lymph node metastases of non-seminomatous germ cell tumours of the testis. , 1993, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[219]  W. See,et al.  Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results. , 1993, The Journal of urology.

[220]  C. Bokemeyer,et al.  Secondary neoplasms following treatment of malignant germ cell tumors. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[221]  N. Jørgensen,et al.  Immunohistochemical expression of embryonal marker TRA‐1–60 in carcinoma in situ and germ cell tumors of the testis , 1993, Cancer.

[222]  A. Karjalainen,et al.  Case-control study of congenital anomalies in children of cancer patients. , 1993, BMJ.

[223]  G. Zagars,et al.  Post-orchiectomy radiotherapy for stages I and II testicular seminoma. , 1993, International journal of radiation oncology, biology, physics.

[224]  K. Dieckmann,et al.  Paternity in a patient with testicular seminoma and contralateral testicular intraepithelial neoplasia. , 1993, International journal of andrology.

[225]  F. Debruyne,et al.  Nerve-sparing retroperitoneal lymphadenectomy for low stage testicular cancer. , 1993, British journal of urology.

[226]  N. Skakkebaek,et al.  Semen quality in testicular tumour and CIS in the contralateral testis , 1993, The Lancet.

[227]  L. Einhorn,et al.  Surgical salvage of chemorefractory germ cell tumors. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[228]  J. Thornhill,et al.  Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. , 1993, The Journal of urology.

[229]  D. Bajorin,et al.  Management of the postchemotherapy residual mass. , 1993, The Urologic clinics of North America.

[230]  R. Motzer,et al.  Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. , 1992, The Journal of urology.

[231]  A. Horwich,et al.  Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[232]  W. van Putten,et al.  Orchidectomy followed by radiotherapy in 176 stage I and II testicular seminoma patients: benefits of a 10-year follow-up study. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[233]  H. Tongaonkar,et al.  Value of retroperitoneal lymph node dissection in advanced testicular seminoma , 1992, Journal of surgical oncology.

[234]  E. Kleinerman,et al.  Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[235]  S. Woolf.  Practice guidelines, a new reality in medicine. II. Methods of developing guidelines. , 1992, Archives of internal medicine.

[236]  A. Horwich,et al.  Surveillance following orchidectomy for stage I testicular seminoma. , 1992, British Journal of Cancer.

[237]  S. Fosså,et al.  Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[238]  N. Skakkebaek,et al.  Management of extragonadal germ-cell tumors and the significance of bilateral testicular biopsies. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[239]  H. Adami,et al.  Occurrence of testicular cancer in patients operated on for cryptorchidism and inguinal hernia. , 1991, The Journal of urology.

[240]  L. Weissbach,et al.  Adjuvant chemotherapy of metastatic stage II nonseminomatous testis tumor. , 1991, The Journal of urology.

[241]  A. Pawinski,et al.  Risk-related adjuvant chemotherapy for stage I non-seminoma of the testis. , 1991, Clinical oncology (Royal College of Radiologists (Great Britain)).

[242]  A. Giwercman,et al.  Placental‐like alkaline phosphatase as a marker of carcinoma‐in‐situ of the testis. Comparison with monoclonal antibodies M2A and 43–9F , 1991, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[243]  J. Ellis,et al.  Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. , 1991, The Journal of urology.

[244]  N. Geller,et al.  Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[245]  E. Nieschlag,et al.  Testosterone: Action, Deficiency, Substitution , 1990 .

[246]  S. Fosså,et al.  Long-term somatic side-effects and morbidity in testicular cancer patients. , 1990, British Journal of Cancer.

[247]  S. Fosså,et al.  Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. , 1989, The Journal of urology.

[248]  D. Stablein,et al.  Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. , 1987, The New England journal of medicine.

[249]  N. Javadpour,et al.  Retroperitoneal Lymphadenectomy with Preservation of Ejaculation , 1987 .

[250]  W. Hendry,et al.  Clinical stage II non-seminomatous germ cell testicular tumours. Results of management by primary chemotherapy. , 1985, British journal of urology.

[251]  C. Logothetis,et al.  Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary report. , 1985, The Journal of urology.

[252]  S. Monfardini,et al.  No adjuvant chemotherapy in selected patients with pathologic stage II nonseminomatous germ cell tumors of the testis. , 1984, The Journal of urology.

[253]  P. Goldstraw,et al.  The role of surgery in the combined management of metastases from malignant teratomas of testis. , 1980, British Journal of Urology.

[254]  A. Horwich,et al.  Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[255]  S. Fosså,et al.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. , 2008, European urology.

[256]  I. Bodrogi,et al.  Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy , 2007, International Urology and Nephrology.

[257]  P. Albers.  Management of stage I testis cancer. , 2007, European urology.

[258]  U. Pichlmeier,et al.  Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. , 2007, European urology.

[259]  K. Dieckmann,et al.  Low-dose radiation therapy for testicular intraepithelial neoplasia , 2005, Journal of Cancer Research and Clinical Oncology.

[260]  S. Fosså,et al.  Patients' and doctors' perception of long-term morbidity in patients with testicular cancer clinical stage I , 2005, Supportive Care in Cancer.

[261]  H. Einsele,et al.  Hematopoietic growth factors and treatment of testicular cancer: Biological interactions, routine use and dose-intensive chemotherapy , 2004, Annals of Hematology.

[262]  A. Horwich,et al.  Initial chemotherapy for stage II testicular non-seminoma , 2004, World Journal of Urology.

[263]  R. Miceli,et al.  A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only. , 2004, The Journal of urology.

[264]  M. Ro̸rth,et al.  Current concepts of radiation treatment of carcinoma in situ of the testis , 2004, World Journal of Urology.

[265]  J. Breza,et al.  Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer , 2004, International Urology and Nephrology.

[266]  K. Pienta,et al.  Testicular Cancer , 2009, Nature Reviews Disease Primers.

[267]  Y. Homma,et al.  Significance of nocturia in the International Prostate Symptom Score for benign prostatic hyperplasia. , 2002, The Journal of urology.

[268]  H. von der Maase.  Do we have a new standard of treatment for patients with seminoma stage IIA and stage IIB? , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[269]  M. Hartmann,et al.  Metachronous contralateral germ cell tumor 7 years after management of testicular intraepithelial neoplasia by chemotherapy and multiple control biopsies. , 2001, Scandinavian journal of urology and nephrology.

[270]  E. Nieschlag,et al.  Andrology : male reproductive health and dysfunction , 2001 .

[271]  L. Einhorn,et al.  Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma--predominant testis cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[272]  April Fritz,et al.  International Classification of Diseases for Oncology: ICD-0. , 2000 .

[273]  U. Pichlmeier,et al.  Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? , 2000, Urology.

[274]  M. Jewett,et al.  Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. , 1998, Seminars in oncology.

[275]  P. Albers,et al.  Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[276]  C. Catton,et al.  Management of stage II seminoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[277]  L. Weissbach,et al.  Elevated human chorionic gonadotropin concentrations in the testicular vein and in peripheral venous blood in seminoma patients. An analysis of various parameters. , 1997, European urology.

[278]  U. Engelmann,et al.  Paternity in patients with bilateral testicular germ cell tumors. , 1997, European urology.

[279]  M. Goepel,et al.  Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma. , 1997, European urology.

[280]  W. Wilmanns,et al.  Late relapse of germ cell tumors after cisplatin-based chemotherapy. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[281]  M. Mason,et al.  Treatment of stage I seminoma: more choices, more dilemmas. , 1997, Clinical oncology (Royal College of Radiologists (Great Britain)).

[282]  M. Theiss,et al.  Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. , 1996, Urologia internationalis.

[283]  E. Nieschlag,et al.  Cryopreservation of semen from adolescent patients with malignancies. , 1996, Medical and pediatric oncology.

[284]  M. Cullen,et al.  Alpha-foetoprotein heterogeneity: what is its value in managing patients with germ cell tumours? , 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).

[285]  L. Weissbach,et al.  Organ preserving surgery of malignant germ cell tumors. , 1995, The Journal of urology.

[286]  J. Richie,et al.  The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). , 1995, The Journal of urology.

[287]  T. Ahlering,et al.  Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. , 1994, Urology.

[288]  E. Oldfield,et al.  Heterogeneity of subcellular localization of p53 protein in human glioblastomas. , 1994, Cancer research.

[289]  W. Wilmanns,et al.  Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease. , 1993, European journal of cancer.

[290]  M. Ro̸rth,et al.  Surveillance following orchidectomy for stage I seminoma of the testis. , 1993, European journal of cancer.

[291]  P. Goodman,et al.  Results of a policy of surveillance in stage I testicular seminoma. , 1993, International journal of radiation oncology, biology, physics.

[292]  L. Einhorn,et al.  Brain metastases and testicular tumors: long-term survival. , 1992, International journal of radiation oncology, biology, physics.

[293]  F. Mostofi,et al.  Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[294]  A. Horwich.  Testicular cancer : investigation and management , 1991 .

[295]  J. Donohue,et al.  Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. , 1990, The Journal of urology.

[296]  L. Weissbach,et al.  Surgical treatment of stage-I non-seminomatous germ cell testis tumor. Final results of a prospective multicenter trial 1982-1987. Testicular Tumor Study Group. , 1990, European urology.

[297]  H. Kienzer,et al.  Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[298]  A. Barrett,et al.  The role of surgery in the combined management of metastases from malignant teratomas of testis. , 1980, British journal of urology.

[299]  H. Fukuda,et al.  European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .